Hospital Universitario De Jaen
- Address
- lock Available on a paid plan
Oncology and Breast Cancer Research
At Hospital Universitario De Jaen, a major share of the clinical trial portfolio focuses on neoplasms, especially breast cancer. Research includes early-stage, locally advanced, metastatic, and high-risk disease, with studies designed to improve treatment effectiveness, reduce recurrence, and refine care after surgery or neoadjuvant therapy.
- Hormone receptor-positive and HER2-negative breast cancer
- HER2-positive and triple-negative breast cancer
- Metastatic and high-risk early breast cancer
- Testing new combinations and supportive strategies to improve outcomes
This work reflects a strong focus on modern oncology care, with trials aimed at better disease control and more personalized treatment choices.
Lung Cancer and Thoracic Oncology
Another prominent area is respiratory tract disease research, particularly non-small cell lung cancer and small cell lung cancer. The trials explore treatment options for advanced, metastatic, and resectable disease, including studies that assess whether newer therapies can improve survival, delay progression, or support care after surgery.
- Advanced and metastatic non-small cell lung cancer
- Small cell lung cancer and limited-stage disease
- EGFR-, RET-, KRAS-, and PD-L1-related lung cancer research
- Evaluating new targeted and immunotherapy-based approaches
This area shows active investigation into more precise and effective treatment strategies for complex lung cancer cases.
Gynecologic, Hepatic, and Other Solid Tumors
The site also studies a broad range of other solid tumors, including ovarian cancer, endometrial cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and prostate cancer. These trials often aim to improve disease control in advanced or recurrent settings and to test whether new regimens can offer better outcomes for patients with limited options.
- Ovarian, endometrial, and fallopian tube cancers
- Head and neck cancer and hepatocellular carcinoma
- Metastatic and unresectable solid tumors
- Assessing new therapies for harder-to-treat cancers
The research portfolio highlights a broad oncology focus beyond breast and lung cancer, with attention to both tumor control and long-term benefit.
Cardiovascular and Metabolic Disease Studies
Clinical trials at the site also address cardiovascular diseases and nutritional and metabolic diseases. Research includes conditions such as atherosclerotic cardiovascular disease, hypertension, spontaneous coronary artery dissection, transthyretin amyloid cardiomyopathy, and type 2 diabetes, with studies focused on improving prevention and treatment.
- Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
- Hypertension, heart failure, and coronary disorders
- Type 2 diabetes and severe hypertriglyceridemia
- Testing therapies that may reduce events and improve long-term health
This research supports better management of chronic cardiometabolic conditions that affect many adults.
Infections, Immune, and Skin-Related Conditions
The trial landscape at Hospital Universitario De Jaen includes studies in bacterial infections and mycoses, immune system diseases, and skin and connective tissue diseases. Examples include bacteremia, septic shock, allergic rhinitis with asthma, and atopic dermatitis, with research aimed at improving treatment effectiveness, safety, and symptom control.
- Bloodstream infections and septic shock
- Allergic and immune-mediated conditions
- Atopic dermatitis and related skin disease
- Comparing treatments to improve outcomes and reduce side effects
These studies show a balanced interest in both acute infectious disease care and longer-term immune-mediated conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 13 therapeutic areas and 15 of 229 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 222 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 43 by active trials.
lock +42 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG8trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Jaen
lock Showing 1 of 134 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 229 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 20 | Unknown | 2018-08-24 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
